Sandoz Pharmaceuticals, the lab mentioned in the Senate MK Ultra document Q posted, merged with Ciba-Geigy Labs in 1996, and the pharma and agrochemical divisions stayed together to form Novartis.
Sandoz discovered LSD in 1943 and marketed it from 1947 through 1963, when it came off the market. These are the drugs marketed under Novartis:
• Clomiparine (brand name – Anafranil) for major depressive disorder and obsessive compulsive disorder (OCD); developed by Geigy and patented in 1963; received FDA approval in 1990; considered gold standard for OCD treatment until SSRIs.
• Clozapine (brand name – Clozaril / Leponex) for treatment-resistant schizophrenia. First synthesized in 1958, but not approved by the FDA until December 2002.
• Iloperidone (brand name – Fanapt, Fanapta, Zomaril) for schizophrenia. First studied in 1995 and approved by the FDA in May 2009
• Dexmethylphenidate (brand name – Focalin) for ADHD; patented by Novartis in 2001 and approved by the FDA in 2008
• Maprotiline (brand name – Ludiomil) for major depressive disorder; developed by CA in 1966 and introduced for medical use in 1974; approved by the FDA in 1988
• Thioridazine (brand name Mellaril) for schizophrenia; withdrawn in 2005 but still available in generic form; launched by Sandoz in 1959 and approved by FDA in 1962
• Methylphenidate (brand name – Ritalin) for ADHD; first synthesized in 1944 by Ciba and identified as a stimulant in 1984; use began in the 1960s to treat children with ADHD or ADD.
• Carbamazepine (brand name – Tegretol) for epilepsy / bipolar disorder / schizophrenia – as a second line agent; first discovered in 1954 by Geigy and marketed as a drug to treat epilepsy in 1963; FDA approved the drug in 1968; in 1971 doctors were using the drug to control patients not responding to antipsychotics and studied for bipolar disorders throughout the 1970s.
• Imipramine (brand name – Tofranil) for major depressive disorder / enuresis (bed-wetting); first discovered in 1951 by Ciba, and marketed for medical use in 1957; use has decreased due to SSRIs.
• Oxcarbazepine (brand name – Trileptal) for epilepsy / bipolar disorder as an add-on therapy; first made in 1965 by Geigy; approved by the FDA in 1990; in September 2010, Novartis pleaded guilty to marketing the drug for the unapproved uses of neuropoathic pain and bipolar disorder.